- Primary research
- Open Access
In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line
© Hoffmeyer et al; licensee BioMed Central Ltd. 2005
Received: 15 November 2004
Accepted: 27 April 2005
Published: 27 April 2005
Inflammatory breast cancer (IBC) is the most lethal form of locally invasive breast cancer known. However, very little information is available on the cellular mechanisms responsible for manifestation of the IBC phenotype. To understand the unique phenotype of IBC, we compared the motile and adhesive interactions of an IBC cell line, SUM 149, to the non-IBC cell line SUM 102.
Our results demonstrate that both IBC and non-IBC cell lines exhibit similar adhesive properties to basal lamina, but SUM 149 showed a marked increase in adhesion to collagen I. In vitro haptotaxis assays demonstrate that SUM 149 was less invasive, while wound healing assays show a less in vitro migratory phenotype for SUM 149 cells relative to SUM 102 cells. We also demonstrate a role for Rho and E-cadherin in the unique invasive phenotype of IBC. Immunoblotting reveals higher E-cadherin and RhoA expression in the IBC cell line but similar RhoC expression. Rhodamine phalloidin staining demonstrates increased formation of actin stress fibers and larger focal adhesions in SUM 149 relative to the SUM 102 cell line.
The observed unique actin and cellular architecture as well as the invasive and adhesive responses to the extracellular matrix of SUM 149 IBC cells suggest that the preference of IBC cells for connective tissue, possibly a mediator important for the vasculogenic mimicry via tubulogenesis seen in IBC pathological specimens. Overexpression of E-cadherin and RhoA may contribute to passive dissemination of IBC by promoting cell-cell adhesion and actin cytoskeletal structures that maintain tissue integrity. Therefore, we believe that these findings indicate a passive metastatic mechanism by which IBC cells invade the circulatory system as tumor emboli rather than by active migratory mechanisms.
With an average five-year post-recovery survival rate of 45%, inflammatory breast cancer (IBC) is the most lethal and aggressive form of locally advanced breast cancer . The lethality of IBC stems from its highly invasive nature. Diagnosis of IBC is often complicated by lack of a palpable precursor lesion commonly associated with breast cancer. Moreover, the correct diagnosis is hindered by inflammatory-like symptoms such as redness, warmth, and edema. Characteristic of IBC is a change in breast skin texture, similar to that of an orange, due to extensive invasion of the dermal lymphatics by IBC tumor cell emboli. These complications contribute to IBC lethality in that by the time a proper diagnosis is made, the cancer has aggressively infiltrated the surrounding tissue and lymphatics system, leading to a lowered patient prognosis . Complicating treatment of this deadly form of breast cancer is that very little information about the cellular mechanisms responsible for the unique IBC phenotype is known.
Cancer cell invasion through the basal lamina and subsequent metastasis involves multiple steps including intravasation through the surrounding tissue into the lymphatic or vascular systems. Transient adhesion to extracellular matrix (ECM) components as well as modification of cell shape by reorganization of the actin cytoskeleton is required for cancer cell infiltration into the adjacent tissue. The Rho GTPases regulate actin cytoskeletal rearrangements, and are thus likely candidates for involvement in cancer cell invasion and metastasis [3, 4]. Further evidence for a relationship between cancer cell mobilization and dysregulation of Rho GTPases is seen in the overexpression of Rho proteins in numerous invasive human cancers. The recent discovery of the overexpression of the Rho isoform RhoC by IBC tumors has been implicated in the physiological mechanisms of this poorly characterized form of breast cancer . RhoC was demonstrated to be overexpressed in metastatic tumors of pancreatic adenocarcinoma patients , murine melanomas , and in the patient-derived IBC cell line SUM 149 . Transient inhibition of RhoC in IBC cells by treatment with farnesyl transferase inhibitors reduced invasion and motility in vitro . Recently it was reported that RhoC overexpression in mammary epithelial cells resulted in a significant increase in cell migration , mediated by the MAPK pathway . These findings led us to hypothesize that RhoC overexpression may promote the highly invasive phenotype of IBC and contribute to the uniquely aggressive phenotype exhibited by IBC.
Another unique feature of IBC is the overexpression of E-cadherin, a transmembrane protein involved in cell-cell adhesion, which is generally lost in highly invasive cancers. It seems somewhat paradoxical that such an aggressive cancer that overexpresses proteins involved in actin cytoskeleton rearrangement and promotion of migration (i.e., RhoC) also overexpresses cell-cell junction proteins such as E-cadherin [11–15]. The literature thus far seems to hold to two schools of thought about the contradictory protein expression seen in IBC. One tends to support the idea that E-cadherin expression fluctuates with disease progression and decreases as IBC cells become invasive . The second school supports the theory of passive metastasis by IBC [11, 12]. In passive metastasis, strong tumor cell-cell adhesions are maintained during dissemination that proceeds via vasculogenesis through secretion of differentiation factors by the tumor cells causing de novo vessel formation . This results in a cancer cell cluster within the vessel, reminiscent of the IBC tumor emboli seen in IBC histology. Furthermore, RhoC overexpression in human mammary epithelial cells has been shown to increase production of angiogenic factors, some of which might mediate passive or active metastasis .
The IBC phenotype has mystified clinicians due to its inflammatory-like symptoms. However IBC symptomology is not considered to be a true immunoreaction, but rather a consequence of cancer cell invasion to the lymphatics system. The mechanism by which IBC invades is unclear and further experimentation with IBC models is required to clarify the exact mechanism by which this form of breast cancer is disseminated. Using the SUM 149 IBC cell line, we have examined the adhesive and migratory capacities in an effort to understand the invasive behavior of IBC for future experimentation with in situ imaging of IBC in animal models. SUM 149 was compared to a control cell line, SUM 102, which was selected because it shares a deletion in the LIBC (lost in inflammatory breast cancer) gene with the SUM 149 cell line but reportedly expresses RhoC mRNA at low levels . We show that SUM 149 is less invasive and adhesive to basal lamina components in vitro than SUM 102, and that SUM 149 expresses more Rho proteins and E-cadherin. These data shows that SUM 149 is not highly motile and therefore possibly not actively invasive, suggesting passive metastasis as the mechanism of IBC dissemination.
Endogenous Levels of Rho
Subcellular Distribution of Focal Adhesions and Filamentous Actin
Because RhoA is involved in actin stress fiber and focal adhesion formation, we stained the cells with rhodamine phalloidin to visualize F-actin and anti-phosphotyrosine to visualize focal adhesions. Figure 1B demonstrates F-actin and focal adhesion distribution in both cell lines. SUM 149 displayed larger focal adhesions and more actin stress fibers than the SUM 102 cell line, as might be expected from the high levels of RhoA in the SUM 149 cell line. Upon stimulation of quiescent cells with EGF or FBS, the SUM 102 cells formed large membrane ruffles (lamellipodia). However, stimulation by both EGF and FBS seemed to have little effect on the actin cytoskeleton of the SUM 149 cells. An increase in focal adhesion was seen in the SUM 149 cells after stimulation with EGF, but no clear cell polarization was observed.
Adhesion to Extracellular Matrix Proteins
Haptotaxis Stimulated Invasion
Subcellular Distribution of Filamentous Actin Subsequent to Cellular Polarization
Endogenous Expression of E-cadherin
IBC is a unique and highly aggressive form of locally advanced breast cancer with distinct clinical presentation. We hypothesized that upregulated expression of RhoC, as reported by others to be characteristic of IBC, contributes to the unusual pathological presentation of IBC. For the first time, we have compared the actin architecture, invasive, and adhesive properties of the IBC cell line SUM 149 with a cell line reported to express less RhoC mRNA compared to SUM 149 but share a deletion in LIBC . Using a commercially available specific antibody to RhoC, we report that RhoC is not overexpressed at the protein level by the IBC cell line SUM 149. Interestingly, we confirmed overexpression of RhoA by utilizing an anti-RhoA specific antibody. However, post-transcriptional regulation of RhoC expression may account for the observed discrepancy. It is possible that our results do not agree with the reported mRNA expression due to specificity problems with the commercially developed antibodies. Furthermore, we demonstrate that, compared to SUM 102, SUM 149 is less invasive and migratory, and displays impaired adhesion to basal lamina components but strong adhesion to connective tissue proteins.
The role of the Rho protein in cancer cell invasion is somewhat controversial. RhoA is known to be involved in cell contractility, both in the formation of bundled actin fibers and through the activation of Rho kinase and subsequent activation of myosin light chain . Such contractile cells have previously been shown to be less motile . However, Rho overexpression has been documented in various human cancers such as bladder and ovarian, and correlates with lymph node invasion, metastasis, and poor patient prognosis [32, 33]. Overexpression of RhoC by human mammary epithelial cells increased invasion, motility, and anchorage independent growth, similar to SUM 149 . Expression of dominant negative Rho T19N has been demonstrated to block melanoma cell invasion . Some investigators report that Rho overexpression has little impact on invasion and cell motility, while others demonstrate a positive correlation between Rho expression and cell migration capacity [35–37]. Rho is required for cell body contraction and tail retraction during directed cell motility, while active Rac and Cdc42 are required for lamellipodia and filopodia extension at the leading edge . Thus, invasive potential is considered to be a balance between Rac, Cdc42, and Rho activities. Overexpression or activation of one of these Rho GTPases will shift this balance and result in a cellular phenotype dominated by the actin structure promoted by the activated Rho GTPase . SUM 149 may display reduced invasion and migration in vitro compared to SUM 102 due to the overexpression of RhoA alone, thus masking the motile effects of Rac and Cdc42.
Another aspect that makes IBC so remarkable is that this form of aggressive breast cancer maintains strong E-cadherin expression [11–15]. Typically, loss of E-cadherin expression correlates with progression to metastatic disease since cancer cells must break inter-cell adhesions before attaining a motile phenotype . Here, we demonstrate that the SUM 149 model of IBC maintains strong E-cadherin expression in culture, as seen in other IBC xenograft models and IBC pathological specimens. Previous reports indicate the E-cadherin axis is also complete and functional . IBC histology reveals an extensive invasion of E-cadherin positive tumor cell emboli within the dermal lymphatics [11–15]. The expression of E-cadherin may be critical for invasion in that IBC is thought by some to be passively disseminated, an invasion mechanism that necessitates cell-cell attachment . In this scenario, tumor cells maintain strong cell-cell connections and enter circulation via vasculogenesis around a tumor cell embolus. Others hold that E-cadherin expression varies with the malignant stage of the disease, and is lost during invasion but reestablished once tumor cells invade the vasculature . The finding reported here, in which the IBC cell line SUM 149 was less invasive and adhesive in vitro compared to the reportedly less aggressive breast cancer cell line SUM 102, seems to support an alternative mode for IBC dissemination from classic actin cytoskeleton- mediated cell motility.
The high expression levels of both E-cadherin and RhoA by SUM 149 may contribute to the uniquely invasive phenotype of IBC. However, signaling via E-cadherin to Rho is unclear with E-cadherin-mediated Rho activation and inhibition reported in a cell line specific manner . Dominant negative RhoA expression in EL and nEαCL cells has been reported to reduce E-cadherin activity . During the embryonic development of stratified epithelium, it was found that α-catenin, Rho, and Rho kinase were vital for coordinated tissue movement. In this sense, cells maintain tissue architecture via cadherin binding but move as a unit through actin reorganization mediated by Rho and its downstream effector Rho kinase . A parallel argument could be made for the dissemination of IBC, in which tightly bound tumor cells move as a coordinated front. This possibility was tested in a wound healing assay, in which we found that the SUM 149 cells do not polarize or move into the wound after 7.5 hours, suggesting that this form of invasion is not the mechanism by which IBC is dissemination.
The SUM cell lines used for the study have been recently developed from pleural effusions of breast cancer patients [18, 19] and are generous gifts of Dr. Stephen Ethier, The University of Michigan, MI. SUM 149 is an IBC cell line that lacks expression of the gene LIBC and overexpresses RhoC . SUM 102, developed from a minimally invasive human breast carcinoma  will be used as a model for non-IBC human breast cancer cells. SUM 149 cells were cultured in F-12 Hams (Gibco™, CA) supplemented with 5% fetal bovine serum (Tissue Culture Biologicals, CA), insulin, and hydrocortisone. SUM 102 cells were cultured in F-12 Hams (Gibco™, CA) supplemented with 5% bovine serum albumin (BSA), epidermal growth factor, T3, ethanolamine, and sodium selenite.
Cell adhesion assays were performed according to . Briefly, glass coverslips (Fisher Scientific, TX) were coated with 50 μg/ml laminin (Gibco BRL, MD), 10 μg/ml of collagen I (BD Biosciences, MA), 10 μg/ml of collagen IV (BD Biosciences, MA) and incubated overnight at 4°C. The coverslips were blocked for 1 hour with 1% heat-denatured BSA (Sigma Chemical Corporation, MO) in PBS. Cells (105) were placed on coverslips and allowed to adhere for 15 minutes. Non-adherent cells were removed by washing. The adherent cells were fixed in 3.7% formaldehyde (Sigma Chemical Corp., MO) and stained for F-actin as described below to aid in quantification. The number of cells per coverslip was quantified with a 40× phase contrast objective.
Haptotaxis Invasion Assay
Cell invasion assays were performed as described in . Modified Boyden chambers (tissue culture treated, 6.5 mm diameter, 10 μm thickness, 8 μm pores, Transwell®, Costar Corp., Cambridge, MA) were coated on the upper surface (invasion), of the membrane with 50 μg/ml laminin, 10 μg/ml collagen I, or 10 μg/ml collagen IV overnight at 4°C and then placed into the lower chamber containing 500 μl culture media with 10% fetal bovine serum (FBS). Serum starved cells (105) were added to the upper surface of each migration chamber and allowed to migrate to the underside of the membrane for 24 hours (invasion). The non-migratory cells on the upper membrane surface were removed with a cotton swab, and the migratory cells attached to the bottom surface of the membrane stained with propidium iodide (CalBioChem-Novabiochem Corp., CA). The number of invasive cells per membrane was counted with an Olympus upright fluorescence microscope with a 40× objective.
Wound Healing Assay
Cells were first grown to a confluent monolayer, wounded with a sterile razor blade and allowed to migrate for 7.5 hours before fixing, permeabilizing, and blocking. Cells were then stained for F-actin as described below and visualized using an Olympus upright fluorescence microscope.
For focal adhesion and F-actin staining, cells were cultured on coverslips until they reached 60% confluency and starved for 24 hours in unsupplemented F-12 Hams. Cells were then stimulated with 50 ng/ml epidermal growth factor (EGF), 5% FBS, or PBS control for 10 minutes, fixed in 3.7% formaldehyde (Sigma Chemical Corp., MO), permeabilized with 0.2% Triton X-100 (Sigma, MO), and blocked with 5% goat serum (Gibco™, CA), and 5% BSA (Sigma Chemical Corp., MO) in PBS. Cells were stained with rhodamine phalloidin (Molecular Probes Inc., OR) to visualize F-actin, and a mouse monoclonal anti-phosphotyrosine antibody, clone 4G10 (Upstate Biotechnology, NY), followed by FITC-conjugated goat anti mouse IgG (ICN Biomedicals Inc., CA) to visualize the focal adhesions. Phosphotyrosine staining to is commonly utilized to visualize focal adhesions . For E-cadherin staining, cells were cultured until 60% confluency, fixed in methanol at -20°C for 15 minutes, and blocked with 5% goat serum (Gibco™, CA) and 5% BSA (Sigma Chemical Corp., MO) in PBS. Cells were stained with a mouse monoclonal anti-E-cadherin antibody, clone G-10 (Santa Cruz Biotechnology, CA) followed by FITC-conjugated goat anti-mouse IgG (ICN Biomedicals Inc., CA). Cells were imaged using an Olympus upright fluorescence microscope with Spot Advanced digital camera software, Version 2.2.1 (Diagnostic Instruments Inc., MI).
Cells were cultured to confluency on 6 cm plates, trypsinized and the pellet washed in 1X PBS. The cell pellet was then lysed in 1% NP-40 lysis buffer. Equal amounts of protein, as determined by Bio-Rad (Hercules, CA) total protein assay, were then separated by 10% SDS-PAGE gel for Rho (A, B, and C), RhoA, and RhoC, or 8% SDS-PAGE gel for E-cadherin. Cellular proteins were then transferred to a nitrocellulose membrane. Membranes were blocked with 4% milk 0.05% Tween and probed with rabbit polyclonal anti-Rho (A, B, and C) (Upstate Biotechnology, NY), mouse monoclonal anti-RhoA (Santa Cruz Biotechnology, CA), goat polyclonal anti-RhoC (Santa Cruz Biotechnology, CA), or mouse monoclonal anti-E-cadherin (Santa Cruz Biotechnology, CA) followed by horseradish peroxidase-conjugated goat anti-mouse antibody (Pierce Endogen, IL) for Rho or alkaline phosphatase conjugated goat anti mouse antibody for E-cadherin (Pierce Endogen, IL). Rho immunoblots were detected with the Super Signal West Femto-Substrate chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax MR film (Fisher Scientific, TX). E-Cadherin immunoblots were detected with NBT/BCIP alkaline phosphatase substrate (Pierce Endogen, IL).
The authors wish to thank Dr. Rebecca Richards-Kortum for critical input during the preparation of this manuscript. This investigation was supported by NIH/NCI CA83957-01A1 and University of Texas Biomedical Engineering Seed Grant to S.D., DOD/US Army BC031906 to M.H, and University of Texas Cooperative Society Awards to KW.
- Levine PH, Steinhorn SC, Ries LG, Aron JL: Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985, 74: 291-297.PubMedGoogle Scholar
- Lopez MJ, Porter KA: Inflammatory breast cancer. Surg Clin North Am. 1996, 76: 411-429.View ArticlePubMedGoogle Scholar
- Schmitz AAP, Govek EE, Ötner BB, van Aelst L: Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 2000, 261: 1-12. 10.1006/excr.2000.5049.View ArticlePubMedGoogle Scholar
- Hall A, Nobes CD: Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos Trans R Soc Lond B Biol Sci. 2000, 355: 965-970. 10.1098/rstb.2000.0632.PubMed CentralView ArticlePubMedGoogle Scholar
- van Golen KL, Davies S, Wu ZF, Wang YF, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999, 5: 2511-2519.PubMedGoogle Scholar
- Suwa H, Ohshio G, Imamura T, Wantanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M: Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer. 1998, 77: 147-152.PubMed CentralView ArticlePubMedGoogle Scholar
- Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000, 406: 532-535. 10.1038/35020106.View ArticlePubMedGoogle Scholar
- van Golen KL, Bao L, DiVito MM, Wu Z, Prendergrast GC, Merajver SD: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002, 1: 575-583.PubMedGoogle Scholar
- van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000, 60: 5832-5838.PubMedGoogle Scholar
- van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD: Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis. 2002, 19: 301-311. 10.1023/A:1015518114931.View ArticlePubMedGoogle Scholar
- Tomlinson JS, Alpaugh ML, Barsky SH: An intact overexpressed E-cadherin/α, β-Catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001, 61: 5231-5241.PubMedGoogle Scholar
- Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH: Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002, 21: 3631-3643. 10.1038/sj.onc.1205389.View ArticlePubMedGoogle Scholar
- Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59: 5079-5084.PubMedGoogle Scholar
- Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA: Inflammatory breast cancer shows angiogenesis with endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003, 10: 718-725. 10.1038/sj.bjc.6600807.View ArticleGoogle Scholar
- Kleer CG, van Golen KL, Braun T, Merajver SD: Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001, 14: 458-464. 10.1038/modpathol.3880334.View ArticlePubMedGoogle Scholar
- Cavallaro U, Christofori G: Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochimica et Biophysica Acta. 2001, 1552: 39-45. 10.1016/S0304-419X(01)00038-5.PubMedGoogle Scholar
- van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia. 2000, 2: 418-425. 10.1038/sj.neo.7900115.PubMed CentralView ArticlePubMedGoogle Scholar
- Ethier SP, Kokeny KE, Ridings JW, Dilts CA: erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res. 1996, 56: 899-907.PubMedGoogle Scholar
- Ethier SP: Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia. 1996, 1: 111-121.View ArticlePubMedGoogle Scholar
- Sartor CI: Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 1997, 57: 978-987.PubMedGoogle Scholar
- Maddox AS, Oegema K: Closing the GAP: A Role for RhoA GAP in Cytokinesis. Mol Cell. 2003, 11: 846-848. 10.1016/S1097-2765(03)00151-5.View ArticlePubMedGoogle Scholar
- Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA: CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998, 140: 961-72. 10.1083/jcb.140.4.961.PubMed CentralView ArticlePubMedGoogle Scholar
- Schoenwaelder SM, Burridge K: Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho. A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases. J Biol Chem. 1999, 274: 14359-67. 10.1074/jbc.274.20.14359.View ArticlePubMedGoogle Scholar
- Sward K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP: The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep. 2003, 5: 66-72.View ArticlePubMedGoogle Scholar
- Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimcry and psuedo-comedo formation in breast cancer. Int J Cancer. 2002, 99: 821-828. 10.1002/ijc.10423.View ArticlePubMedGoogle Scholar
- Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62: 560-566.PubMedGoogle Scholar
- Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, Wakasugi H: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001, 61: 445-451.PubMedGoogle Scholar
- Nobes CD, Hall A: Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol. 1999, 144: 1235-1244. 10.1083/jcb.144.6.1235.PubMed CentralView ArticlePubMedGoogle Scholar
- Okegawa T, Li Y, Pong RC, Hsieh JT: Cell adhesion proteins as tumor suppressors. J Urol. 2002, 167: 1836-43. 10.1097/00005392-200204000-00091.View ArticlePubMedGoogle Scholar
- Ridley AJ: Rho GTPases and cell migration. J Cell Sci. 2001, 114: 2713-2722.PubMedGoogle Scholar
- Rottner K, Hall A, Small JV: Interplay between Rac and Rho in the control of substrate contact dynamics. Curr Biol. 1999, 9: 640-648. 10.1016/S0960-9822(99)80286-3.View ArticlePubMedGoogle Scholar
- Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003, 9: 2632-41.PubMedGoogle Scholar
- Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 2003, 83: 861-70.View ArticlePubMedGoogle Scholar
- Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000, 406: 532-5. 10.1038/35020106.View ArticlePubMedGoogle Scholar
- Stam JC, Michiels F, van der Kammen RA, Moolenaar WH, Collard JG: Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J. 1998, 17: 4066-4074. 10.1093/emboj/17.14.4066.PubMed CentralView ArticlePubMedGoogle Scholar
- Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999, 5: 221-225. 10.1038/5587.View ArticlePubMedGoogle Scholar
- O'Connor KL, Nguyen BK, Mercurio AM: RhoA function in lamellae formation and migration is regulated by the alpha6beta4 integrin and cAMP metabolism. J Cell Biol. 2000, 148: 253-258. 10.1083/jcb.148.2.253.PubMed CentralView ArticlePubMedGoogle Scholar
- Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS: A balance of signaling by Rho family small GTPases RhoA, Rac1, and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene. 1999, 18: 47-57. 10.1038/sj.onc.1202262.View ArticlePubMedGoogle Scholar
- Braga VMM: Cell-cell adhesion and signalling. Curr Opin Cell Biol. 2002, 14: 546-556. 10.1016/S0955-0674(02)00373-3.View ArticlePubMedGoogle Scholar
- Fukata M, Kaibuchi K: Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol. 2001, 2: 887-897. 10.1038/35103068.View ArticlePubMedGoogle Scholar
- Vaezi A, Bauer C, Vasioukhin V, Fuchs E: Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. Dev Cell. 2002, 3: 367-381. 10.1016/S1534-5807(02)00259-9.View ArticlePubMedGoogle Scholar
- Hendrix MJC, Softer EA, Meltzer PS, Gardner LMG, Hess AR, Kirschmann DA, Schatteman GC, Seftor REB: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. Proc Nat Acd Sci USA. 2001, 98: 8018-8023. 10.1073/pnas.131209798.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.